Certara (CERT) – Accelerating Medicines with Biosimulation
As seen on CNBC** Certara is the global leader in biosimulation, a powerful and proven…
CertaraApril 27, 2021
Planning a Health Canada PRCI Compliant Submission
How to set yourself up for a successful Health Canada PRCI submission
CertaraApril 26, 2021
Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
CertaraApril 21, 2021
Part 2: Oligonucleotide therapeutic development: Pre-clinical and translational considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
CertaraApril 21, 2021
Part 1: What are oligonucleotide therapeutics, and how do they work?
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
CertaraApril 21, 2021
Plan to Accelerate Your Time to Drug Submissions
There are common themes driving how quickly you can get from your last database lock…
CertaraApril 20, 2021
A Best Practice Framework for Applying PBPK Modeling to Pediatric Drug Development
Pediatric PBPK models have broad application in the drug development process and are being used…
CertaraApril 20, 2021
Overcome Research Hurdles: Expert Guidance for Complex Generic Drug Development
Do expensive bioequivalence studies stall your generic drug approval? Learn how you can streamline complex…
CertaraApril 15, 2021
Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States
Authors: Joseph McGuirk, Clint Divine, Seung Hyun Moon, Aastha Chandak, Zhiji Zhang, Genovefa A. Papanicolaou…
CertaraApril 8, 2021
Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure
The European Medicines Agency (EMA) recently approved dulaglutide (Trulicity®) at higher doses (3 mg and…
CertaraApril 1, 2021
